Research graph
References from The Ethical and Practical Issues of Market Exclusivity for Naturally Derived Dermatologic Medications: The Case of Cantharidin. Local targets link to admitted publications; unresolved targets remain external evidence.
Cantharidin Revisited: A Blistering Defense of an Ancient Medicine
10.1001/archderm.137.10.1357 · 2001 · External reference
Ethical issues of compounding cantharidin in dermatology
10.1016/j.jaad.2022.07.020 · 2023 · External reference
Cantharidin Topical Solution 0.7%: First Approval
10.1007/s40272-023-00600-y · 2024 · External reference
Unresolved reference
2018 · External reference
The Vexing Voyage of Vasopressin
10.1016/j.chest.2022.02.048 · 2022 · External reference
Frequently Asked Questions on Patents and Exclusivity
2026 · External reference
Incentives for Drug Development — The Curious Case of Colchicine
10.1056/nejmp1003126 · 2010 · External reference
ASHP-PPAG Guidelines for Providing Pediatric Pharmacy Services in Hospitals and Health Systems
2018 · External reference
Unresolved reference
External reference
Unresolved reference
2026 · External reference
Topical Nitrogen Mustard in the Management of Mycosis Fungoides: Update of the Stanford Experience
10.1001/archderm.139.2.165 · 2003 · External reference
Unresolved reference
2014 · External reference
Unresolved reference
External reference
Comprehensive Management of Molluscum Contagiosum: Assessment of Clinical Associations, Comorbidities, and Management Principles
2023 · External reference
Cutaneous warts: an evidence-based approach to therapy
2005 · External reference
